A heart transplant is an operation in which the diseased heart in a person is replaced with a healthy heart from a deceased donor. Ninety percent of heart transplants are performed on patients with end-stage heart failure.
Heart failure is a condition in which the heart is damaged or weakened and can't pump enough blood to meet the body's needs. "End-stage" means the condition has become so severe that all treatments, other than heart transplant, have failed.
A technique borrowed from neuroscience to see through brain tissue is helping scientists to see the fine structure of the heart.
The first known identification of two genes responsible for hypoplastic left heart syndrome (HLHS), a severe congenital heart defect, has been reported by researchers at the University of Pittsburgh School of Medicine.
A new record for original science submissions has been set for the world's leading heart failure congress. In addition to the main abstract programme, highly anticipated results from major studies will be presented in the late breaking trial sessions.
A new study in mice reveals that eosinophils, a type of disease-fighting white blood cell, appear to be at least partly responsible for the progression of heart muscle inflammation to heart failure in mice.
A global outbreak of Mycobacterium chimaera, an invasive, slow-growing bacterium, is linked to heater-cooler devices (HCD) used in cardiac surgery, according to a study published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
The cornea is a transparent tissue lining the front of the eye, that is invisible tissue to the naked eye. It is a delicate tissue and disease or injury may lead to a loss of transparency or a change in the shape of the cornea, resulting in severe visual impairment.
A clinical study - known as IRONMAN - will determine if iron supplement injections could ease the disabling symptoms of heart failure. The trial was officially launched today at the British Cardiovascular Society Conference in Manchester.
End-stage heart failure patients treated with stem cells harvested from their own bone marrow experienced 37 percent fewer cardiac events - including deaths and heart failure hospital admissions - than a placebo-controlled group, according to a new study.
A review article has been published in the journal Current Pharmaceutical Design which provides an overview of therecent literature discussing the different clinical forms of heart disease resulting from virus infections including the prognosis, and current therapies.
A surgical team at Baylor University Medical Center at Dallas successfully performed a heart transplant on a patient they were keeping alive with a total artificial heart, a portable device that pumps blood throughout the body when both sides of the heart fail.
To determine patient eligibility for heart transplant, the International Society for Heart Lung Transplantation maintains a list of criteria, first issued in 2006, that acts as a guideline for physicians.
One week ago, surgical teams took part in a record-setting day of organ transplantation at Baylor University Medical Center at Dallas. Surgeons on the medical staff performed nine organ transplants on seven patients in one calendar day.
Peripartum cardiomyopathy (PPCM) is a rare disorder characterized by weakened pumping of the heart, or "left ventricular dysfunction," which results in otherwise healthy pregnant women experiencing heart failure shortly before or up to five months after they deliver healthy babies. Despite the seriousness of this condition, a new study published in the Canadian Journal of Cardiology revealed that no significant research has been undertaken to explore how to prevent or treat this disorder.
Using fresh whole blood from single donors is better than using component blood from multiple donors in pediatric heart surgery patients, according to an article in the May 2015 issue of The Annals of Thoracic Surgery.
Heart transplant surgeons from Mayo Clinic are presenting findings from three recent clinical studies involving heart transplant patients. The presentations took place during the 2015 International Society of Heart & Lung Transplant in Nice, France, on April 15-18.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that data from its first destination therapy clinical trial cohort, ENDURANCE, successfully demonstrated that the trial achieved the primary endpoint.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from Health Canada, the country's federal department responsible for helping Canadians maintain their health, to market the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.
The Cedars-Sinai Heart Institute completed 120 adult heart transplants and two adult heart-lung transplants in 2014, setting a new national standard for the most adult heart transplants performed in a single year.
Pediatric cardiology researchers and clinicians from numerous centers from around the world are gathering at the Cardiology 2015: the 18th Annual Update on Pediatric and Congenital Cardiovascular Disease conference, sponsored by The Children's Hospital of Philadelphia and Phoenix Children's Hospital on Feb. 11 to Feb. 15 in Scottsdale, Ariz.
Many aspects of pediatric cardiology are relatively new to the discipline. Only recently have physicians been able to accurately diagnose and characterize the myriad congenital cardiovascular conditions that occur and begin to apply successful strategies for care. This week, an international group of more than 800 medical experts gather at the nation's largest pediatric cardiology conference to discuss challenges in treating congenital heart disease in the fetus, neonates, children and young adults.